INAB - IN8bio Inc

1.53
-0.030   -1.961%

Share volume: 52,977
Last Updated: 04-28-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.20%

PREVIOUS CLOSE
CHG
CHG%
$1.56
-0.03
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.00%
1 Month
11.68%
3 Months
-23.50%
6 Months
-23.50%
1 Year
789.53%
2 Year
54.53%
Key data
Stock price
$1.53
P/E Ratio 
N/A
DAY RANGE
$1.52 - $1.60
EPS 
-$2.08
52 WEEK RANGE
$0.10 - $4.17
52 WEEK CHANGE
$805.33
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$74,692
AVERAGE 30 VOLUME 
$59,728
Company detail
CEO: William T. Ho
Region: US
Website: in8bio.com
Employees: 20
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, which is in Phase I clinical trial for glioblastoma and solid tumors. InB-100, an allogeneic product candidate, is in clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.

Recent news